Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Horizon's Revised TED Indication Should Help Tepezza

Good News For Amgen, But Viridian Looms As Competition

14 Apr 2023

• By Joseph Haas

eye disease — Revised indication for Tepezza should mean broader patient access within TED • Source: Shutterstock

Related Content

TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza

15 Aug 2022

Horizon Provides Assurances That Tepezza Sales Are Set To Soar

05 May 2022

Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover

12 Dec 2022

Related Companies

Horizon Therapeutics plc

Amgen, Inc.

Viridian Therapeutics, Inc.

Additional Topics

Clinical Trials Business Strategies Companies Deals Drug Approval Standards Commercial Ophthalmic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.